tiprankstipranks
Spruce Biosciences (SPRB)
NASDAQ:SPRB

Spruce Biosciences Stock Analysis & Ratings

SPRB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.25 - $15.86
Previous Close$1.47
VolumeN/A
Average Volume (3M)238.54K
Market Cap$34.53M
P/E Ratio-0.8
Beta2.48
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-1.81


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

SPRB FAQ

What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $1.25 and its highest was $15.86 in the past 12 months.
    What is Spruce Biosciences’s market cap?
    Spruce Biosciences’s market cap is $34.53M.
      What is Spruce Biosciences’s price target?
      The average price target for Spruce Biosciences is $9.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $20.00 ,the lowest forecast is $3.00. The average price target represents 546.26% Increase from the current price of $1.47.
        What do analysts say about Spruce Biosciences?
        Spruce Biosciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Spruce Biosciences’s upcoming earnings report date?
          Spruce Biosciences’s upcoming earnings report date is Aug 09, 2022 which is in 83 days.
            How were Spruce Biosciences’s earnings last quarter?
            Spruce Biosciences released its earnings results on May 11, 2022. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.042.
              Is Spruce Biosciences overvalued?
              According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
                Does Spruce Biosciences pay dividends?
                Spruce Biosciences does not currently pay dividends.
                What is Spruce Biosciences’s EPS estimate?
                Spruce Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Spruce Biosciences have?
                Spruce Biosciences has 23,490,000 shares outstanding.
                  What happened to Spruce Biosciences’s price movement after its last earnings report?
                  Spruce Biosciences reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went up 1.563%.
                    Which hedge fund is a major shareholder of Spruce Biosciences?
                    Among the largest hedge funds holding Spruce Biosciences’s share is Omega Fund Management, LLC. It holds Spruce Biosciences’s shares valued at 4M.

                      ---

                      Spruce Biosciences Stock Analysis

                      The Spruce Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Spruce Biosciences

                      Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

                      ---
                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis